Afamelanotide
MC1R agonist
Also Scenesse, Melanotan I, Melanotan 1, MT-1, MT-I, CUV1647
- Evidence
- AStrong human evidence
- FDA status
- FDA approvedas of 2026-10-26
- Route
- Implant
- Studies cited
- 3 human0 animal or cell
An implant that lets people with a rare sun-pain disease stay in daylight longer. Trials in 168 adults show it works for that, but none show it works for tanning.
Sold for
Afamelanotide is best known as the first drug for EPP, a rare disease in which sunlight causes burning pain, and in its earlier life as a candidate 'sunless tan' because it darkens skin.
Studies say
Randomized trials show it lengthens the time EPP patients can spend in sunlight without pain, which earns grade A for that indication; there are no trials supporting cosmetic tanning.
Why grade A. Two randomized, double-blind, placebo-controlled trials in 168 adults with EPP (94 in the United States, 74 in the European Union) showed more pain-free hours in sunlight, and a 117-patient post-authorisation cohort followed for about two years confirmed the effect in routine practice. Consensus guidelines recommend it for preventing phototoxic symptoms. The evidence is strong for EPP and nonexistent for the tanning use the compound is also known for. 567
FDA. Afamelanotide is FDA-approved and sold as Scenesse, a subcutaneous implant, approved in October 2019 to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP). The European Medicines Agency authorised it for the same disease in 2014. 134
Written from 9 cited sources. Last refreshed 2026-10-27. Not physician reviewed.
What this means for you
- What people take it for
- Staying in sunlight without pain, in the rare disease EPP.
- Can a US doctor prescribe it?
- Yes, FDA approved for adults with EPP, a rare disease where sunlight causes pain.
- Properly tested in people?
- Yes, in large controlled trials: two trials in 168 adults.
Evidence checklist
- Randomised controlled trial Two placebo-controlled trials in EPPyes
- Human study over 100 people 168 trial patients; 117-patient cohortyes
- More than one research group US and EU trials plus Dutch academic cohortyes
- Clinical outcomes, not surrogate markers Pain-free sun time, phototoxic reactionsyes
- Human safety data beyond case reports Trials, two-year cohort and label datayes
Drawn from the cited studies below. A dash means the sources give no information.
What it is
Afamelanotide is a synthetic 13-amino-acid analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), the natural peptide that tells pigment cells to make melanin. Two amino acid substitutions make it more stable and more potent than the natural hormone. It was developed in the 1980s at the University of Arizona and later taken through clinical trials by Clinuvel Pharmaceuticals. 12
The approved product, Scenesse, is a small rod implanted under the skin by a healthcare professional and left to dissolve over about two months. It is a prescription drug supplied through a restricted programme in the United States. 18
How it works
Afamelanotide activates the melanocortin-1 receptor (MC1R) on melanocytes, the pigment cells of the skin. Activation increases production of eumelanin, the brown-black form of melanin, without the need for ultraviolet light. 1
In EPP, a genetic enzyme defect causes protoporphyrin IX to accumulate in red blood cells and skin. Visible light, including wavelengths outside the ultraviolet range, excites this molecule and triggers a burning phototoxic reaction within minutes. Extra eumelanin absorbs some of that light before it reaches the protoporphyrin, and eumelanin also has antioxidant properties that may blunt the reaction. 15
What human research shows
Two multicentre randomized trials published together in 2015 enrolled 168 adults with EPP. In the United States study (94 patients, 270 days), the median pain-free time in direct sunlight was 69.4 hours with afamelanotide versus 40.8 hours with placebo. In the European Union study (74 patients, 180 days), the figures were 6.0 hours versus 0.8 hours, and phototoxic reactions were fewer (77 versus 146). Quality of life improved in both trials. 5
A post-authorisation cohort study at Erasmus MC followed 117 EPP patients on afamelanotide for a median of two years. Time spent outdoors rose by an added 6.1 hours per week, disease-specific quality of life scores improved by about 14%, and phototoxic reactions were less painful though not fewer; 98% of patients stayed on treatment. 6
Evidence-based consensus guidelines for EPP and X-linked protoporphyria published in 2023 recommend afamelanotide for preventing phototoxic symptoms, alongside sun avoidance and monitoring for liver disease and vitamin D deficiency. 7
| Study | Model | Finding |
|---|---|---|
| Langendonk 2015, NEJM (US trial) | Humans, n=94 adults with EPP, randomized double-blind placebo-controlled, 270 days | Median pain-free sunlight exposure 69.4 hours with afamelanotide versus 40.8 hours with placebo. 5 |
| Langendonk 2015, NEJM (EU trial) | Humans, n=74 adults with EPP, randomized double-blind placebo-controlled, 180 days | Median pain-free time 6.0 versus 0.8 hours; phototoxic reactions 77 versus 146. 5 |
| Wensink 2020, JAMA Dermatology | Humans, n=117, prospective post-authorisation cohort, median 2 years | Time outdoors increased by 6.1 hours per week, quality of life improved, reactions were less painful, 98% continued treatment. 6 |
| EPP consensus guidelines 2023 | Systematic review and expert consensus | Afamelanotide is recommended for preventing phototoxic symptoms in EPP and X-linked protoporphyria. 7 |
Safety
In the phase 3 trials adverse events were mostly mild, and serious events were judged unrelated to the drug. The commonest reported effects are implant-site reactions, nausea, headache, fatigue and skin darkening, which is the intended pharmacological effect. In the two-year Dutch cohort, side effects were minor and self-limiting. 56
The US label warns of serious hypersensitivity reactions, including anaphylaxis, and advises full-body skin examinations because the drug darkens existing moles and freckles and could make melanoma harder to spot. Whether MC1R stimulation changes melanoma risk over decades is not known; the trials were too short and too small to answer that. Unregulated 'melanotan' products sold online for tanning are different compounds with no manufacturing oversight. 28
Questions for your clinician
- Is there any controlled human trial for the use I have in mind, such as tanning?
- How often would my skin need checking while I have an implant?
- What are the signs of a hypersensitivity reaction to the implant?
Questions people ask
Is afamelanotide FDA-approved?
Yes. Scenesse was approved in October 2019 for adults with a history of phototoxic reactions from erythropoietic protoporphyria. It had been authorised in the European Union since 2014. 134
Is afamelanotide the 'Barbie drug'?
That nickname attached to the compound in the 2000s because it darkens skin without sun. The approved drug is used only for EPP. Illicit 'melanotan' tanning injections sold online are not afamelanotide and have no quality control. 2
Citations
- FDA: Scenesse (afamelanotide) prescribing information, 2019 accessdata.fda.gov
- McGill Office for Science and Society: the 'Barbie drug' mcgill.ca
- EMA: Scenesse European public assessment report ema.europa.eu
- BioSpace 2019: FDA approves first treatment to increase pain-free light exposure in EPP biospace.com
- Langendonk 2015, NEJM: afamelanotide for erythropoietic protoporphyria pubmed.ncbi.nlm.nih.gov
- Wensink 2020, JAMA Dermatology: afamelanotide outcomes in clinical practice pubmed.ncbi.nlm.nih.gov
- J Am Acad Dermatol 2023: consensus guidelines for EPP and X-linked protoporphyria pubmed.ncbi.nlm.nih.gov
- DailyMed: Scenesse label, warnings and precautions dailymed.nlm.nih.gov
- Langendonk 2015, NEJM (DOI) doi.org